Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2018

28.12.2017 | Thoracic Oncology

Perioperative Risk Calculator Predicts Long-Term Oncologic Outcome for Patients with Esophageal Carcinoma

verfasst von: Masashi Takeuchi, MD, Hiroya Takeuchi, MD, PhD, Hirofumi Kawakubo, MD, PhD, Eisuke Booka, MD, PhD, Shuhei Mayanagi, MD, PhD, Kazumasa Fukuda, PhD, Rieko Nakamura, MD, PhD, Koichi Suda, MD, PhD, Norihito Wada, MD, PhD, Yuko Kitagawa, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Few risk models have been provided to predict long-term prognosis after esophagectomy. This study investigated the reliability of a risk calculator as well as classification and regression trees analysis for predicting long-term prognosis after esophagectomy for esophageal cancer.

Methods

The study enrolled 438 patients who underwent esophagectomy at Keio University Hospital, Tokyo, Japan, between July 2000 and June 2016. Patients who underwent R0 or R1 resection or esophagectomy with combined resection of other organs were included. The authors investigated the usefulness of a risk model for 30-day mortality and operative mortality described in their previous report for predicting long-term prognosis after esophagectomy.

Results

The 438 patients (377 men and 61 women) in this study had a 5-year overall survival (OS) rate of 62.8% and a disease-free survival rate of 54.3%. The OS was higher for the patients with 30-day mortality risk model values lower than 0.675% than for those with values higher than 0.675% (p < 0.001). The cutoff values for prediction were shown to be significant risk factors in the multivariate analysis. The risk calculator was validated by comparing the cutoff values with Harrell’s C-index values of clinical stage. For overall risk, the C-index of operative mortality was 0.697, and the C-index of cStage was 0.671.

Conclusions

The risk calculator was useful for predicting recurrence and death after esophagectomy. Furthermore, because the C-index of the risk model for operative mortality was higher than for clinical tumor-node-metastasis stage, this risk-scoring system may be more useful clinically.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Takeuchi H, Miyata H, Gotoh M, et al. A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide web-based database. Ann Surg. 2014;260:259–66.CrossRefPubMed Takeuchi H, Miyata H, Gotoh M, et al. A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide web-based database. Ann Surg. 2014;260:259–66.CrossRefPubMed
2.
Zurück zum Zitat Kidane B, Sulman J, Xu W, et al. Baseline measure of health-related quality of life (functional assessment of cancer therapy-esophagus) is associated with overall survival in patients with esophageal cancer. J Thorac Cardiovasc Surg. 2016;151:1571–80.CrossRefPubMed Kidane B, Sulman J, Xu W, et al. Baseline measure of health-related quality of life (functional assessment of cancer therapy-esophagus) is associated with overall survival in patients with esophageal cancer. J Thorac Cardiovasc Surg. 2016;151:1571–80.CrossRefPubMed
3.
Zurück zum Zitat Hamai Y, Hihara J, Emi M, et al. Ability of fluorine-18 fluorodeoxyglucose positron emission tomography to predict outcomes of neoadjuvant chemoradiotherapy followed by surgical treatment for esophageal squamous cell carcinoma. Ann Thorac Surg. 2016;102:1132–39.CrossRefPubMed Hamai Y, Hihara J, Emi M, et al. Ability of fluorine-18 fluorodeoxyglucose positron emission tomography to predict outcomes of neoadjuvant chemoradiotherapy followed by surgical treatment for esophageal squamous cell carcinoma. Ann Thorac Surg. 2016;102:1132–39.CrossRefPubMed
4.
Zurück zum Zitat Takeuchi H, Saikawa Y, Oyama T, et al. Factors influencing the long-term survival in patients with esophageal cancer who underwent esophagectomy after chemoradiotherapy. World J Surg. 2010;34:277–84.CrossRefPubMed Takeuchi H, Saikawa Y, Oyama T, et al. Factors influencing the long-term survival in patients with esophageal cancer who underwent esophagectomy after chemoradiotherapy. World J Surg. 2010;34:277–84.CrossRefPubMed
5.
Zurück zum Zitat Booka E, Takeuchi H, Nishi T, et al. The impact of postoperative complications on survivals after esophagectomy for esophageal cancer. Med Baltim. 2015;94:e1369.CrossRefPubMedPubMedCentral Booka E, Takeuchi H, Nishi T, et al. The impact of postoperative complications on survivals after esophagectomy for esophageal cancer. Med Baltim. 2015;94:e1369.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Matsuda S, Takeuchi H, Kawakubo H, et al. Cumulative prognostic scores based on plasma fibrinogen and serum albumin levels in esophageal cancer patients treated with transthoracic esophagectomy: comparison with the Glasgow prognostic score. Ann Surg Oncol. 2015;22:302–10.CrossRefPubMed Matsuda S, Takeuchi H, Kawakubo H, et al. Cumulative prognostic scores based on plasma fibrinogen and serum albumin levels in esophageal cancer patients treated with transthoracic esophagectomy: comparison with the Glasgow prognostic score. Ann Surg Oncol. 2015;22:302–10.CrossRefPubMed
7.
Zurück zum Zitat Sobin L, Gospodarowicz M WC, eds. TNM Classification of Malignant Tumours. 7th ed Wiley-Liss, New York, 2009. Sobin L, Gospodarowicz M WC, eds. TNM Classification of Malignant Tumours. 7th ed Wiley-Liss, New York, 2009.
8.
Zurück zum Zitat Matsuda S, Takeuchi H, Kawakubo H, et al. Clinical outcome of transthoracic esophagectomy with thoracic duct resection: number of dissected lymph node and distribution of lymph node metastasis around the thoracic duct. Med Baltim. 2016;95:e3839.CrossRef Matsuda S, Takeuchi H, Kawakubo H, et al. Clinical outcome of transthoracic esophagectomy with thoracic duct resection: number of dissected lymph node and distribution of lymph node metastasis around the thoracic duct. Med Baltim. 2016;95:e3839.CrossRef
9.
Zurück zum Zitat Kaburagi T, Takeuchi H, Kawakubo H, et al. Clinical utility of a novel hybrid position combining the left lateral decubitus and prone positions during thoracoscopic esophagectomy. World J Surg. 2014;38:410–18.CrossRefPubMed Kaburagi T, Takeuchi H, Kawakubo H, et al. Clinical utility of a novel hybrid position combining the left lateral decubitus and prone positions during thoracoscopic esophagectomy. World J Surg. 2014;38:410–18.CrossRefPubMed
10.
Zurück zum Zitat Takesue T, Takeuchi H, Ogura M, et al. A prospective randomized trial of enteral nutrition after thoracoscopic esophagectomy for esophageal cancer. Ann Surg Oncol. 2015;22:802–09.CrossRef Takesue T, Takeuchi H, Ogura M, et al. A prospective randomized trial of enteral nutrition after thoracoscopic esophagectomy for esophageal cancer. Ann Surg Oncol. 2015;22:802–09.CrossRef
11.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Breiman L, Friedman JH, Stone CJ, et al. Classification and regression trees. 1984;1:368. Breiman L, Friedman JH, Stone CJ, et al. Classification and regression trees. 1984;1:368.
13.
Zurück zum Zitat Garzotto M, Beer TM, Hudson RG, et al. Improved detection of prostate cancer using classification and regression tree analysis. J Clin Oncol 2005;23:4322–29.CrossRefPubMed Garzotto M, Beer TM, Hudson RG, et al. Improved detection of prostate cancer using classification and regression tree analysis. J Clin Oncol 2005;23:4322–29.CrossRefPubMed
14.
Zurück zum Zitat Loh W-Y. Classification and regression trees. Wiley Interdiscip. Rev. 2011;1:14–23. Loh W-Y. Classification and regression trees. Wiley Interdiscip. Rev. 2011;1:14–23.
15.
Zurück zum Zitat Okamura A, Takeuchi H, Matsuda S, et al. Factors affecting cytokine change after esophagectomy for esophageal cancer. Ann Surg Oncol. 2015;22:3130–35.CrossRefPubMed Okamura A, Takeuchi H, Matsuda S, et al. Factors affecting cytokine change after esophagectomy for esophageal cancer. Ann Surg Oncol. 2015;22:3130–35.CrossRefPubMed
16.
Zurück zum Zitat Ogura M, Takeuchi H, Kawakubo H, et al. Clinical significance of CXCL-8/CXCR-2 network in esophageal squamous cell carcinoma. Surgery. 2013;154:512–20.CrossRefPubMed Ogura M, Takeuchi H, Kawakubo H, et al. Clinical significance of CXCL-8/CXCR-2 network in esophageal squamous cell carcinoma. Surgery. 2013;154:512–20.CrossRefPubMed
17.
Zurück zum Zitat Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol. 2003;10:972–92.CrossRefPubMed Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol. 2003;10:972–92.CrossRefPubMed
18.
Zurück zum Zitat Hogan BV, Peter MB, Shenoy HG, et al. Surgery-induced immunosuppression. Surgeon. 2011;9:38–43.CrossRefPubMed Hogan BV, Peter MB, Shenoy HG, et al. Surgery-induced immunosuppression. Surgeon. 2011;9:38–43.CrossRefPubMed
19.
Zurück zum Zitat Goldfarb Y, Sorski L, Benish M, et al. Improving postoperative immune status and resistance to cancer metastasis. Ann Surg. 2011;253:798–810.CrossRefPubMed Goldfarb Y, Sorski L, Benish M, et al. Improving postoperative immune status and resistance to cancer metastasis. Ann Surg. 2011;253:798–810.CrossRefPubMed
20.
21.
Zurück zum Zitat Ferri LE, Law S, Wong KH, et al. The influence of technical complications on postoperative outcome and survival after esophagectomy. Ann Surg Oncol. 2006;13:557–64.CrossRefPubMed Ferri LE, Law S, Wong KH, et al. The influence of technical complications on postoperative outcome and survival after esophagectomy. Ann Surg Oncol. 2006;13:557–64.CrossRefPubMed
22.
Zurück zum Zitat Feng JF, Huang Y, Lu WS CQ. Preoperative platelet count in esophageal squamous cell carcinoma: is it a prognostic factor? Langenbecks Arch Surg. 2013;398:1115.CrossRefPubMed Feng JF, Huang Y, Lu WS CQ. Preoperative platelet count in esophageal squamous cell carcinoma: is it a prognostic factor? Langenbecks Arch Surg. 2013;398:1115.CrossRefPubMed
23.
Zurück zum Zitat Shimada H, Oohira G, Okazumi S, et al. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg. 2004;198:737–41.CrossRefPubMed Shimada H, Oohira G, Okazumi S, et al. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg. 2004;198:737–41.CrossRefPubMed
24.
Zurück zum Zitat Tsuruo T, Fujita N. Platelet aggregation in the formation of tumor metastasis. Proc Japan Acad Ser B, Phys Biol Scienes. 2008;84:189–98.CrossRef Tsuruo T, Fujita N. Platelet aggregation in the formation of tumor metastasis. Proc Japan Acad Ser B, Phys Biol Scienes. 2008;84:189–98.CrossRef
25.
Zurück zum Zitat Reeh M, Metze J, Uzunoglu FG, et al. The PER (Preoperative Esophagectomy Risk) Score: a simple risk score to predict short-term and long-term outcome in patients with surgically treated esophageal cancer. Medicine Baltimore. 2016;95:1–8.CrossRef Reeh M, Metze J, Uzunoglu FG, et al. The PER (Preoperative Esophagectomy Risk) Score: a simple risk score to predict short-term and long-term outcome in patients with surgically treated esophageal cancer. Medicine Baltimore. 2016;95:1–8.CrossRef
26.
Metadaten
Titel
Perioperative Risk Calculator Predicts Long-Term Oncologic Outcome for Patients with Esophageal Carcinoma
verfasst von
Masashi Takeuchi, MD
Hiroya Takeuchi, MD, PhD
Hirofumi Kawakubo, MD, PhD
Eisuke Booka, MD, PhD
Shuhei Mayanagi, MD, PhD
Kazumasa Fukuda, PhD
Rieko Nakamura, MD, PhD
Koichi Suda, MD, PhD
Norihito Wada, MD, PhD
Yuko Kitagawa, MD, PhD
Publikationsdatum
28.12.2017
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 3/2018
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6311-7

Weitere Artikel der Ausgabe 3/2018

Annals of Surgical Oncology 3/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.